The search for broad-spectrum antivirals has intensified as respiratory pathogens continue evolving, making multi-target compounds increasingly valuable for future pandemic preparedness. Traditional antiviral drugs often target single viral proteins, creating vulnerability to resistance mutations that could render treatments ineffective.
Galloylquinic acids extracted from Copaifera lucens leaves demonstrate potent antiviral activity against SARS-CoV-2 through a sophisticated dual-inhibition strategy. These bioactive compounds achieved 93% viral suppression at 200 µg/mL concentrations while maintaining low cellular toxicity (CC50: 387.7 µg/mL). The therapeutic window proves remarkably wide, with a selective index of 102 indicating the compounds target viral processes far more effectively than host cell functions. Laboratory testing revealed the extract disrupts multiple viral lifecycle stages: blocking 80% of initial viral attachment and preventing 85.6% of intracellular replication.
This multi-target approach represents a strategic advantage over current antivirals. While remdesivir and molnupiravir each target single viral enzymes, galloylquinic acids simultaneously inhibit the spike protein's receptor-binding domain and RNA polymerase complex. Molecular modeling confirms these compounds form stable interactions through hydrogen bonding and electrostatic forces at both binding sites. Such dual targeting could prove invaluable against future viral variants, as simultaneous mutations affecting both target sites would be evolutionarily costly for the virus. The research advances our understanding of how plant-derived polyphenolic compounds might serve as scaffolds for next-generation antivirals, particularly given their established safety profiles in traditional medicine. However, human trials remain necessary to validate therapeutic potential and optimal dosing strategies.